Clinical trials: Induction Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Acupuncture for Chemotherapy-Induced Nausea and Vomiting
The purpose of this study is to clarify whether the matching acupoints is more effective than a single point by electroacupuncture in the management of chemotherapy-induced nausea and vomiting .
- Trial name
- NCT02195921
- Testing
- single point Zhongwan(CV12) plus antiemetic drug, single point Zusanli(ST36) plus antiemetic drug, Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tianjin University of Traditional Chinese Medicine
Non-small Cell Lung Cancer
Navelbine And Radiotherapy in Locally Advanced Lung Cancer
This study is an open label randomized multi-centre phase II trial in patients with inoperable locally advanced stage IIB-IIIB Non Small Cell Lung Cancer who fulfils the general criteria for curatively intended irradiation.
- Trial name
- NARLAL (NCT00887783)
- Testing
- Navelbine, 66 Gy/33F, 60 Gy/30F
- Where
- 6 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Odense University Hospital
Chemotherapy-induced Nausea and Vomiting
Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
- Trial name
- NCT05319860
- Testing
- Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Oral Mucositis
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
The initial proposed clinical study will be conducted in adult head and neck cancer subjects. This will be an open-labeled, proof of concept trial to evaluate the efficacy, safety and tolerability of EISO in a form of oral rinse…
- Trial name
- NCT02399228
- Testing
- 0.25% EISO mouth rinse
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Head and Neck Cancer
Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ECHO-07 (NCT00665392)
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 8 sites in France
- Volunteers
- 42 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Chemotherapy-induced Neutropenia
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Determination of the effect of balugrastim on the duration and severity of severe neutropenia.
- Trial name
- NEUGR-002 (NCT00837265)
- Testing
- Balugrastim, Pegfilgrastim, Chemotherapy Regimen
- Volunteers
- 334 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
- Trial name
- NCT02665143
- Testing
- Nintedanib and AML induction
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Ovarian Cancer, Uterine Cancer
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies.
- Trial name
- NCT01432015
- Testing
- fosaprepitant, aprepitant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gynecologic Oncology Associates
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
- Trial name
- RECITE (NCT03362177)
- Testing
- Romiplostim
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 165 people
- Sponsor
- Amgen
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy
This is a double blind, randomized, crossover pilot study of Voxx Human Performance Technology Socks versus placebo socks for the treatment of chemotherapy-induced peripheral neuropathy in patients with cancer.
- Conditions
- Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy, Neuropathy
- Trial name
- NCT04403802
- Testing
- Voxx Human Performance Technology Socks
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Arash Asher, MD
Prostate Cancer
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer.
- Trial name
- NCT00024167
- Testing
- Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium
- Where
- 40 sites in United States
- Volunteers
- 265 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy.
- Trial name
- NCT01144364
- Testing
- rituximab [Mabthera/Rituxan]
- Where
- 45 sites in Italy
- Volunteers
- 234 people
- Sponsor
- Hoffmann-La Roche
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Endometrial Cancer
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258362
- Testing
- carboplatin, docetaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Adult Acute Myeloid Leukemia, Adult Myelodysplastic Syndrome
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
This pilot clinical trial studies the feasibility of having induction chemotherapy in an outpatient setting. Patients with acute leukemia (AML) or advanced myelodysplastic syndrome (MDS), at least 18 years of age will be…
- Trial name
- NCT01807091
- Testing
- Chemotherapy
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Alcoholism
Varenicline (Chantix™) for the Treatment of Alcohol Dependence
The purpose of this study is to determine the efficacy of varenicline (Chantix™) for the treatment of alcohol dependence.
- Trial name
- ChA (NCT00705523)
- Testing
- varenicline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
This randomized, open-label, parallel-group study will assess the efficacy and s afety of Avastin (bevacizumab) in combination with chemotherapy versus chemother apy alone as second- and third-line therapy in patients with…
- Trial name
- NCT01250379
- Testing
- bevacizumab [Avastin], Chemotherapy
- Where
- 132 sites in Argentina, Austria and 11 more
- Volunteers
- 494 people
- Sponsor
- Hoffmann-La Roche
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC